BaltaSDemirkolSCelikTUnluMArslanZHaqmalH. Triple antiplatelet therapy in obese patients undergoing stent implantation [published online March 11, 2013]. Angiology. 2013. doi: 10.1177/0003319713480425
2.
CuissetTFrereCQuiliciJ. High post-treatment platelet reactivity identified low responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4(3):542–549.
3.
MarcucciRGoriAMPanicciaR. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. Circulation. 2009;119(2):237–242.
4.
AlHabibKFHersiAAlsheikh-AliAA. Prevalence, predictors, and outcomes of conservative medical management in non-ST segment elevation acute coronary syndromes in Gulf RACE-2. Angiology. 2012;63(2):109–118.
5.
ChenKYRhaSWLiYJ; KoreaAcute Myocardial Infarction Registry Investigators. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009;119(25):3207–3214.
6.
WangZJZhouYJLiuYY. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res. 2009;124(1):46–51.
7.
WangZJZhouYJLiuYY. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart. 2009;95(19):1587–1592.
8.
GaoWZhangQGeHGuoYZhouZ. Angiology efficacy and safety of triple antiplatelet [published online January 27, 2013]. Angiology. 2013.
